Tag: Start up

PlumeSTARS among the 16 SMEs for access to the Match Business Call in Silicon Valley 2019

The Silicon Valley is the nerve center of the global startup and innovation ecosystem, where the majority of investment collection opportunities are gathered, strategic partners and global business contacts are sought.

Since 2015, the Emilia-Romagna Region has been present in Silicon Valley through the ASTER Consortium Company, which manages regional internationalization projects towards Silicon Valley and the permanent facility in San Francisco. Since 2017, the Emilia-Romagna Region has expanded its activities to involve not only the startups, but the whole regional innovative ecosystem, starting from the most innovative companies.

PlumeSTARS was chosen among the 16 companies on the list that have passed the pre-assessment and are therefore invited to participate in the boot camp on 25, 26 and 27 June 2019 in Bologna.

The Business Match program and the related boot camp are managed by ART-ER thanks to funds from the Emilia-Romagna Region. Topics of the Emilia-Romagna actions in Silicon Valley, with the collaboration of the USMAC partner – US Market Access Center. The co-CEOs of the Company, Alfredo Coppola and Chris Burry, will be in Bologna to hold the boot camp.

The boot camp is an intensive training on how to do business with Silicon Valley, but also an evaluation step of the Call: at the end of the boot camp, in fact, the 8 companies that will access the Business Match service program in Silicon Valley itself.

PLUMESTARS ATTENDED THE 59TH AFI SYMPOSIUM

Also for this year, PlumeSTARS participated at the 59th AFI Symposium, the Italian Conference of the Industrial Pharmacists, held on 5, 6 and 7 June at the new Pala Congressi in Rimini.

The AFI Symposium is the important conference that for almost 60 years involves the interlocutors of the pharmaceutical sector at an international level, and this is why it is confirmed year by year an important moment of encounter and exchange between the protagonists of scientific research and the Companies. As for the update exam of great importance and considerable authority.

It consists of several scientific sessions, culminates with the Lectio magistralis and the Plenary Session and also includes spaces dedicated to:

  • The startup square, for young companies in the pharma-biotechnology world and medical and diagnostic devices, divided into short conferences focused on technology transfer in the presence of leading experts in the sector, with the aim of creating a network with companies in the world pharmaceutical;
  • Workshops with companies in the sector;
  • 10 technological innovations, where the latest proposals of the companies selected by the AFI Board that exhibit at the Symposium are presented;

PlumeSTARS presented, in a speech of Prof. Paolo Colombo (PlumeStars CEO), “Hyalcis: Hyaluronic-Cisplatin Film for Implant for Malignant Mesothelioma Recurrences”.

Hyalcis exploits nanotechnology and advanced material research results to bring to market an innovative medical treatment of mesothelioma. The studies until now conducted revealed an interaction between the polymer hyaluronic acid and cisplatin that gave rise to a drug-polymer complex, lymphatically absorbed and blood distributed.

The uptake by pharmaceutical industry of the hyaluronic- cisplatin film technology studied by PlumeStars will assign a more effective cure against recurrences of this rare and very aggressive form of cancer that is difficult to diagnose and highly resistant to anticancer drugs.

The film requires an advanced manufacturing process in order to guarantee its quality, in particular sterility.

Hyalcis combines a known active principle, cisplatin, with a polymeric material, hyaluronic acid, providing an innovative solution to post-surgery prevention of mesothelioma recurrences. The novel product has a demonstrable added value compared to the presently applied chemotherapy (IV or pleura surface washing) and radiotherapy treatments, since it allows a strict dose control and implantation easiness.

Hyalcis transfers the PlumeStars research results to the cancer therapy. PlumeStars technology could be transferred to treat other forms of cancer, thus multiplying the beneficial impact for society (e.g. ovarian cancer) and market.

The innovation provides clear societal benefits by more efficiently addressing a relevant illness form which full recovery is extremely rare.

TVLP program

Ten start ups in Silicon Valley, including Plumestars srl

There are ten Emilian-Romagna start ups, five of which belong to the food industry, who will experience on the field what it means to operate in Silicon Valley.

Until November 15, 2015, the first edition of a course that will become a permanent training mechanism in Silicon Valley, the world center for creating start-up innovations, will kick off.

In fact, the Emilia-Romagna Region, supported by Aster, has launched the Aster in Usa program, a subsidiary in Silicon Valley to support start-ups that want to internationalize their market, seek new funding and increase their skills.

Read more “Ten start ups in Silicon Valley, including Plumestars srl”

Co-funded by the European Union

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Unisciti a 3 altri iscritti

Archive